AS is a process of closely monitoring men with low-risk prostate cancer through PSA blood tests, digital rectal exams (DREs), ultrasounds, and prostate biopsies, with the goal of averting active treatment unless disease progression is detected or the patient chooses treatment [4, 5]. The gene discussed is KLK3; the disease is prostate cancer.